OBJECTIVE: HIV alters host responses to hepatitis C virus (HCV). However, the impact of antiretroviral therapy (ART) on HCV is rarely understood in relevant tissues and never before within individual hepatocytes. DESIGN: HIV and HCV kinetics were studied before and after ART initiation among 19 HIV/HCV co-infected persons. From five persons with the largest decline in plasma HCV RNA, liver tissues collected before and during ART, when plasma HIV RNA was undetectable, were studied. METHODS: We used single-cell laser capture microdissection and quantitative PCR to assess intrahepatic HCV. Immunohistochemistry was performed to characterize intrahepatic immune cell populations. RESULTS: Plasma HCV RNA declined by 0.81 (0.52-1.60) log10 IU/ml from a median (range) 7.26 (6.05-7.29) log10 IU/ml and correlated with proportions of HCV-infected hepatocytes (r = 0.89, P = 2 × 10-5), which declined from median (range) of 37% (6-49%) to 23% (0.5-52%) after plasma HIV clearance. Median (range) HCV RNA abundance within cells was unchanged in four of five participants. Liver T-cell abundance unexpectedly decreased, whereas natural killer (NK) and NK T-cell infiltration increased, correlating with changes in proportions of HCV-infected hepatocytes (r = -0.82 and r = -0.73, respectively). Hepatocyte expression of HLA-E, an NK cell restriction marker, correlated with proportions of HCV-infected hepatocytes (r = 0.79). CONCLUSION: These are the first data to show that ART control of HIV reduces the intrahepatic burden of HCV. Furthermore, our data suggest that HIV affects the pathogenesis of HCV infection by an NK/NK T-cell-mediated mechanism that may involve HLA-E and can be rescued, at least in part, by ART.
OBJECTIVE: HIV alters host responses to hepatitis C virus (HCV). However, the impact of antiretroviral therapy (ART) on HCV is rarely understood in relevant tissues and never before within individual hepatocytes. DESIGN: HIV and HCV kinetics were studied before and after ART initiation among 19 HIV/HCV co-infected persons. From five persons with the largest decline in plasma HCV RNA, liver tissues collected before and during ART, when plasma HIV RNA was undetectable, were studied. METHODS: We used single-cell laser capture microdissection and quantitative PCR to assess intrahepatic HCV. Immunohistochemistry was performed to characterize intrahepatic immune cell populations. RESULTS: Plasma HCV RNA declined by 0.81 (0.52-1.60) log10 IU/ml from a median (range) 7.26 (6.05-7.29) log10 IU/ml and correlated with proportions of HCV-infected hepatocytes (r = 0.89, P = 2 × 10-5), which declined from median (range) of 37% (6-49%) to 23% (0.5-52%) after plasma HIV clearance. Median (range) HCV RNA abundance within cells was unchanged in four of five participants. Liver T-cell abundance unexpectedly decreased, whereas natural killer (NK) and NK T-cell infiltration increased, correlating with changes in proportions of HCV-infected hepatocytes (r = -0.82 and r = -0.73, respectively). Hepatocyte expression of HLA-E, an NK cell restriction marker, correlated with proportions of HCV-infected hepatocytes (r = 0.79). CONCLUSION: These are the first data to show that ART control of HIV reduces the intrahepatic burden of HCV. Furthermore, our data suggest that HIV affects the pathogenesis of HCV infection by an NK/NK T-cell-mediated mechanism that may involve HLA-E and can be rescued, at least in part, by ART.
Authors: Abraham J Kandathil; Sho Sugawara; Ashish Goyal; Christine M Durand; Jeffrey Quinn; Jaiprasath Sachithanandham; Andrew M Cameron; Justin R Bailey; Alan S Perelson; Ashwin Balagopal Journal: J Clin Invest Date: 2018-09-10 Impact factor: 14.808
Authors: Shadi Salloum; Jacinta A Holmes; Rohit Jindal; Shyam S Bale; Cynthia Brisac; Nadia Alatrakchi; Anna Lidofsky; Annie J Kruger; Dahlene N Fusco; Jay Luther; Esperance A Schaefer; Wenyu Lin; Martin L Yarmush; Raymond T Chung Journal: Hepatology Date: 2016-10-05 Impact factor: 17.425
Authors: Rasmi Thomas; Chloe L Thio; Richard Apps; Ying Qi; Xiaojiang Gao; Darlene Marti; Judy L Stein; Kelly A Soderberg; M Anthony Moody; James J Goedert; Gregory D Kirk; W Keith Hoots; Steven Wolinsky; Mary Carrington Journal: J Virol Date: 2012-04-11 Impact factor: 5.103
Authors: E Papasavvas; L Azzoni; X Yin; Q Liu; J Joseph; A Mackiewicz; B Ross; K M Lynn; J M Jacobson; K Mounzer; J R Kostman; L J Montaner Journal: J Viral Hepat Date: 2017-05-11 Impact factor: 3.728
Authors: Lisa N Wasilewski; Ramy El-Diwany; Supriya Munshaw; Anna E Snider; Jillian K Brady; William O Osburn; Stuart C Ray; Justin R Bailey Journal: J Virol Date: 2016-01-27 Impact factor: 5.103
Authors: Wenyu Lin; Ethan M Weinberg; Andrew W Tai; Lee F Peng; Mark A Brockman; Kyung-Ah Kim; Sun Suk Kim; Carolina B Borges; Run-Xuan Shao; Raymond T Chung Journal: Gastroenterology Date: 2008-01-10 Impact factor: 22.682
Authors: Veron Ramsuran; Vivek Naranbhai; Amir Horowitz; Ying Qi; Maureen P Martin; Yuko Yuki; Xiaojiang Gao; Victoria Walker-Sperling; Gregory Q Del Prete; Douglas K Schneider; Jeffrey D Lifson; Jacques Fellay; Steven G Deeks; Jeffrey N Martin; James J Goedert; Steven M Wolinsky; Nelson L Michael; Gregory D Kirk; Susan Buchbinder; David Haas; Thumbi Ndung'u; Philip Goulder; Peter Parham; Bruce D Walker; Jonathan M Carlson; Mary Carrington Journal: Science Date: 2018-01-04 Impact factor: 47.728